Quick Answer: In 2026, pharmaceutical manufacturer patient assistance programs provide free or deeply discounted brand-name drugs to patients whose household income falls below 200% to 400% of the federal poverty level, depending on the program. Major programs include NovoCare (Novo Nordisk, income up to 200% FPL for Ozempic), Lilly Cares Foundation (Eli Lilly, income up to 300-500% FPL by drug group), Bristol Myers Squibb Patient Assistance Foundation (BMSPAF, income up to 400% FPL for Eliquis), Pfizer RxPathways (income up to 300% FPL), myAbbVie Assist (AbbVie, income-verified), and BI Cares Foundation (Boehringer Ingelheim, income-verified for Jardiance). Federal anti-kickback law bars manufacturer copay savings cards from patients with Medicare, Medicaid, TRICARE, or VA benefits, but the separate income-based PAPs remain available to eligible government-insurance holders. The 2026 Part D annual out-of-pocket cap is $2,100 for all Medicare Part D drugs combined.
Pharmaceutical manufacturer patient assistance programs (PAPs) are a critical but underused safety net for patients who cannot afford their brand-name prescription drugs in 2026. Most major drug companies operate independent charitable foundations or internal programs that supply their brand-name medications free of charge, or at nominal cost, to qualifying patients. Eligibility in 2026 is almost always gated on three factors: household income relative to the federal poverty level (FPL), lack of adequate prescription drug coverage, and US residency. The income bar varies by program and by drug: NovoCare caps Ozempic eligibility at 200% FPL for uninsured patients, while Lilly Cares Foundation uses a tiered structure of 300% to 500% FPL depending on the specific Lilly drug. Most programs require annual re-enrollment and a new prescriber signature each year.
Manufacturer savings cards (sometimes called copay cards or copay coupons) are different from income-based PAPs. Savings cards reduce the copay for commercially-insured patients, often to $0 or $25 per month. Federal anti-kickback statute (42 U.S.C. Section 1320a-7b) bars manufacturers from offering savings cards to anyone covered by Medicare, Medicaid, TRICARE, or VA benefits. Patients on these government programs who cannot afford their prescription must apply for the separate income-based PAP rather than the savings card. For patients with Medicare Part D, the 2026 annual out-of-pocket cap of $2,100 under the Inflation Reduction Act provides a parallel safety net, and Medicare Extra Help (the Low-Income Subsidy) can further reduce costs for enrollees with income at or below approximately $23,475 in 2026.
Three free navigator databases help patients find the right PAP without navigating each manufacturer's website separately. NeedyMeds (needymeds.org) covers about 4,700 medications and is reachable by phone at 1-800-503-6897. RxAssist (rxassist.org) indexes nearly 100 manufacturer programs and over 700 drugs. PhRMA's Medicine Assistance Tool (medicineassistancetool.org) searches most major brand-name drug PAPs simultaneously. Patients who use these databases avoid common scam sites that charge fees to 'apply' for programs that are always free. Medicaid income limits and Medicare eligibility thresholds are additional programs worth checking before spending time on a manufacturer PAP, since Medicaid often provides broader coverage at lower cost for qualifying households.
What Patient Assistance Programs Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same patient assistance programs can cost many times more at a hospital than at your local pharmacy:
2026 Patient Assistance Programs Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Manufacturer PAP (income up to 400% FPL, uninsured or underinsured) | $0/month for approved drugs | Drug supplied free directly from manufacturer. Processing 2-14 business days. Annual renewal required. |
| Manufacturer savings card (commercially insured patients only) | $0 - $25/month typical | Blocked for Medicare, Medicaid, TRICARE, and VA patients by federal anti-kickback statute. For commercially-insured patients only. |
| Medicare Part D with Extra Help (Low-Income Subsidy) 2026 | $5.10 - $12.65/prescription copay maximum | Income up to $23,475/year (single) or $31,725 (married couple) in 2026. Apply at ssa.gov or call 1-800-772-1213. |
| Medicare Part D (standard, no Extra Help) 2026 | Varies by plan; annual OOP capped at $2,100 for 2026 | The 2026 $2,100 cap is set by the Inflation Reduction Act. Once you reach $2,100 in annual out-of-pocket Part D spending, you pay $0 for covered drugs for the rest of the year. |
| Medicaid (income-eligible households) | $1 - $4/prescription copay | Eligibility varies by state. Medicaid income limits vary; most states cover adults up to 138% FPL under ACA expansion. Check your state's Medicaid income limits. |
PAP income thresholds use 2026 HHS federal poverty guidelines. Program terms are subject to change annually. Always verify current terms directly with the manufacturer.
Source: CMS Medicare Part D 2026 benefit parameters, HHS 2026 federal poverty guidelines, manufacturer PAP program pages
Why Hospitals Charge So Much
Hospital outpatient pharmacies and inpatient pharmacy departments routinely charge prices for brand-name prescription drugs that are 2 to 5 times higher than retail cash prices. When a patient is admitted to a hospital and receives a brand-name drug they normally fill at an outpatient pharmacy, the hospital applies its own acquisition markup, pharmacy overhead, and facility fee, all of which are layered on top of the drug's wholesale acquisition cost. A drug that costs $500 per month at a retail pharmacy can appear on an inpatient itemized bill at $1,500 to $2,500. The manufacturer patient assistance program does not apply to inpatient hospital settings because hospitals purchase the drug themselves and bill the payer separately.
Patients who use manufacturer PAPs for their outpatient prescriptions should be aware that the PAP benefit does not extend to any hospital-billed drug charges. If you are admitted to a hospital while enrolled in a PAP, request an itemized bill after discharge and compare each drug line item against the drug's wholesale acquisition cost or the National Drug Code (NDC) list price. Charges substantially above the wholesale acquisition cost are common targets for appeal. Use the Medical Bill Analyzer to flag hospital drug charges that may be negotiable.
Patient Assistance Programs
The six largest pharmaceutical manufacturer PAPs in 2026 are listed below with their income thresholds, covered drugs, and application contacts. Without insurance, a single patient household earning below $63,840 per year (400% FPL for household size 1 in 2026) may qualify for free drugs under several of these programs. The manufacturer coupon and savings card programs listed separately in this guide are for commercially insured patients only and cannot be combined with government insurance by law.
Patient assistance programs for Patient Assistance Programs| Manufacturer program | Cost / Benefit | How to apply |
|---|
| NovoCare Patient Assistance Program (Novo Nordisk) | Free Ozempic for uninsured patients at or below 200% FPL; free insulin and other Novo drugs for patients up to 400% FPL in 2026 | https://www.novocare.com/diabetes/help-with-costs/pap.html |
| Lilly Cares Foundation Patient Assistance Program (Eli Lilly) | Free Humalog, Basaglar, Trulicity, Mounjaro, and other Lilly drugs. Income up to 300% FPL (Group 1), 400% FPL (Group 2), or 500% FPL (Groups 3 and 4) in 2026 | https://www.lillycares.com/how-to-apply |
| Bristol Myers Squibb Patient Assistance Foundation (BMSPAF) | Free Eliquis, Orencia, Sotyktu, and other BMS drugs. Income up to 400% FPL. Applies to both uninsured and underinsured patients in 2026 | https://www.bmspaf.org/ |
| Pfizer RxPathways Patient Assistance Program | Free Pfizer drugs for patients with income up to 300% FPL in 2026. Includes Prevnar, Xeljanz, and many other Pfizer-branded medications | https://www.pfizerrxpathways.com/our-programs |
| myAbbVie Assist (AbbVie) | Free Humira, Skyrizi, Rinvoq, Imbruvica, and other AbbVie drugs. Income-verified eligibility. Medicare patients below 150% FPL need a Part D Extra Help denial letter | https://www.abbvie.com/patients/patient-support/patient-assistance.html |
| BI Cares Foundation Patient Assistance Program (Boehringer Ingelheim) | Free Jardiance and other BI drugs for patients with no prescription drug insurance or limited coverage who meet income guidelines. Income criteria established by BI Cares Foundation | https://www.boehringer-ingelheim.com/us/about-us/sustainable-development/our-commitment/how-apply |
Manufacturer savings cards (copay cards, manufacturer coupons) are separate from PAPs and are not available to beneficiaries of Medicare, Medicaid, TRICARE, or VA by law (federal anti-kickback statute, 42 U.S.C. Section 1320a-7b). If you have government insurance, you must use the income-based PAP instead. Medicare patients with high drug costs should also check eligibility for Medicare Extra Help (Low-Income Subsidy) at ssa.gov, which can reduce Part D copays to $5.10 to $12.65 per prescription in 2026.
Source: NovoCare (novocare.com), Lilly Cares Foundation (lillycares.com), BMSPAF (bmspaf.org), Pfizer RxPathways (pfizerrxpathways.com), myAbbVie Assist (abbvie.com), BI Cares Foundation (boehringer-ingelheim.com), NeedyMeds (needymeds.org)
Medicare Part D
Medicare Part D enrollees face specific rules when interacting with manufacturer patient assistance programs in 2026. The Inflation Reduction Act capped annual Part D out-of-pocket spending at $2,100 for all covered drugs combined, meaning most Medicare beneficiaries will spend no more than $2,100 per year on their Part D prescriptions regardless of how many or how expensive. Once the $2,100 threshold is crossed in a calendar year, the patient pays $0 for covered drugs for the remainder of that year. Medicare beneficiaries who struggle to reach the $2,100 cap should also consider Medicare Extra Help (Low-Income Subsidy), which reduces Part D copays to $5.10 per generic and $12.65 per brand-name drug per prescription for qualifying enrollees with income up to $23,475 per year (single person) or $31,725 per year (married couple) in 2026.
Medicare Part D beneficiaries who want to use a manufacturer income-based PAP (as opposed to a savings card) can do so legally in most cases, though some PAPs restrict eligibility for Medicare Part D patients. The key distinction is between the savings card or manufacturer coupon (always prohibited for Medicare patients by federal anti-kickback statute) and the separate income-based PAP or free drug program (allowed for Medicare patients who meet income and coverage requirements). For IRA-negotiated drugs such as Eliquis (apixaban), Medicare beneficiaries pay the Maximum Fair Price starting January 1, 2026, which already reflects a significant reduction from the prior list price. Always confirm with your specific manufacturer program whether Medicare Part D enrollment disqualifies you from PAP participation.
Common Patient Assistance Programs Billing Errors
Patients enrolled in manufacturer PAPs or using savings cards frequently encounter these billing errors. Review your pharmacy receipts and explanation of benefits carefully for these issues:
- Manufacturer savings card applied to a Medicare account: pharmacies sometimes accept the card at point of sale without confirming Medicare status. This is an anti-kickback statute violation. The claim will be clawed back and you may owe the full price retroactively. Verify before every fill that your pharmacist knows your insurance status.
- PAP drug shipped but pharmacy also billed your insurance for the same prescription, resulting in a duplicate charge. Confirm with your pharmacy whether your PAP supply should also generate an insurance claim.
- Formulary tier misclassification: your plan placed the drug on a higher formulary tier than required. Ask your prescriber to file a formulary tier exception if a lower-tier equivalent exists or if the drug is medically necessary at the current tier.
- Part D out-of-pocket cap not applied after reaching $2,100 in 2026: if you have reached $2,100 in total Part D out-of-pocket spending for the year, you should pay $0 for covered drugs. If your pharmacy is still charging a copay, call your Part D plan to have the claim reprocessed.
- Prior authorization lapsed without renewal notice: many drugs require annual or biennial prior authorization renewals. If your PA lapses, the pharmacy will charge you the full cash price. Set a calendar reminder 60 days before your PA expiration date.
Frequently Asked Questions
What is a patient assistance program and how does it work?
A patient assistance program (PAP) is a manufacturer-funded program that provides free or very low-cost brand-name prescription drugs to patients who cannot afford them. Most major pharmaceutical companies run these programs through independent charitable foundations. In 2026, eligibility is typically based on three factors: household income at or below a specified percentage of the federal poverty level (commonly 200% to 400% FPL), lack of adequate prescription drug coverage, and US residency. Approved patients receive the drug shipped directly to their home or prescriber's office at no cost. Annual renewal with updated income documentation is required. All programs are free to apply; never pay a third-party service to apply.
How do I apply for a manufacturer patient assistance program in 2026?
To apply for a manufacturer PAP in 2026: first, identify your drug's manufacturer using NeedyMeds (needymeds.org) or RxAssist (rxassist.org). Second, visit the manufacturer's official website to download the application form. Third, complete both the patient section and your prescriber's section (your doctor must sign). Fourth, gather income documentation (tax return or pay stubs), proof of US residency, and your prescription. Fifth, submit by the manufacturer's preferred method: online portal, fax, or mail. Processing takes 2 to 14 business days. Approved patients receive medication at no charge. Major programs: NovoCare (novocare.com), Lilly Cares (lillycares.com), BMSPAF (bmspaf.org), Pfizer RxPathways (pfizerrxpathways.com), myAbbVie Assist (abbvie.com/patients).
Can I use a manufacturer savings card or coupon if I have Medicare?
No. Federal anti-kickback statute (42 U.S.C. Section 1320a-7b) prohibits manufacturers from offering copay savings cards or manufacturer coupons to patients enrolled in Medicare, Medicaid, TRICARE, or VA benefits. This is a federal law, not a manufacturer policy. If you have Medicare and cannot afford your prescription, your options are: apply for the manufacturer's separate income-based PAP (which is legal for Medicare patients), apply for Medicare Extra Help (Low-Income Subsidy) at ssa.gov if your income is at or below $23,475 per year in 2026, or check whether your Medicare Part D plan has a lower-cost formulary alternative. The 2026 Part D annual out-of-pocket cap of $2,100 also limits maximum annual exposure for Medicare patients.
What is the income limit to qualify for a patient assistance program in 2026?
Income limits vary by manufacturer and by drug. In 2026, the most common thresholds are: NovoCare caps Ozempic eligibility at 200% FPL ($31,920 for household size 1); Lilly Cares Foundation uses 300% to 500% FPL by drug group; BMSPAF (Eliquis) uses approximately 400% FPL ($63,840 for household size 1); Pfizer RxPathways uses 300% FPL ($47,880 for household size 1); myAbbVie Assist verifies income case-by-case with no published single cutoff. All income thresholds use 2026 HHS federal poverty guidelines. Use the household-size table on this page to see exact dollar thresholds at 400% FPL for family sizes 1 through 8.
Is there a generic or biosimilar alternative to my brand-name drug?
For many brand-name drugs, a generic or biosimilar alternative exists that can dramatically lower cost without requiring a manufacturer PAP application. Generic drugs (for small-molecule drugs like metformin, atorvastatin, lisinopril) are typically 60 to 85 percent cheaper than the brand. Biosimilars (for biologic drugs like adalimumab, etanercept, adalimumab) are typically 15 to 35 percent cheaper than the reference biologic. Ask your prescriber whether an FDA-approved generic or biosimilar is therapeutically appropriate for your condition. If a generic exists, it is usually the fastest and cheapest route to affordable access without waiting for PAP approval.
What does the Inflation Reduction Act do for prescription drug costs in 2026?
The Inflation Reduction Act of 2022 made three major changes to prescription drug costs effective in 2026. First, the annual Medicare Part D out-of-pocket cap is $2,100 in 2026 (down from no cap before the IRA). Second, ten drugs negotiated under the IRA have reduced Maximum Fair Prices effective January 1, 2026, including Eliquis (apixaban), Jardiance (empagliflozin), Xarelto (rivaroxaban), Januvia (sitagliptin), Farxiga (dapagliflozin), Entresto, Enbrel, Imbruvica, Stelara, and Fiasp/NovoLog. Third, the insulin $35 monthly cap for Medicare Part D insulin has been in effect since January 2023. These IRA benefits apply to Medicare patients only and do not directly reduce retail cash prices.
What if my insurance denies coverage for my drug?
If your plan denies coverage in 2026, follow these steps: (1) Request a written denial notice with the specific reason. (2) Ask your prescriber to file a prior authorization or peer-to-peer review immediately. Most denials are overturned when the prescriber documents medical necessity. (3) File a formal appeal within 60 days of denial. Your plan is required to respond within statutory deadlines. (4) If step therapy is required, ask your prescriber to file a step-therapy override documenting why the required first-line drug is inappropriate for you. (5) If all appeals fail, apply for the manufacturer PAP as a fallback. NeedyMeds (needymeds.org) and RxAssist (rxassist.org) can help identify the correct program within minutes.
Do I qualify for a patient assistance program if I have commercial insurance but still cannot afford my copay?
Most manufacturer PAPs require that you have no prescription drug insurance or that your insurance does not cover the specific drug. However, many manufacturers also offer separate copay assistance programs (manufacturer coupons or savings cards) specifically for commercially-insured patients who face high copays. These savings cards can reduce copays to $0 or $25 per month for eligible brand-name drugs. If your commercially-insured copay is still unaffordable after applying the savings card, some manufacturers also offer a hardship PAP track that considers income even for insured patients. Contact the manufacturer's patient support line to ask about all available options for your specific drug and insurance situation.
